94 related articles for article (PubMed ID: 15099777)
1. Interleukin-7 and suppression of local peritoneal immunity in ovarian carcinoma.
Xie X; Ye D; Chen H; Lu W; Cheng B; Zhong H
Int J Gynaecol Obstet; 2004 May; 85(2):151-8. PubMed ID: 15099777
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma.
Chen LL; Ye F; Lü WG; Yu Y; Chen HZ; Xie X
J Obstet Gynaecol Res; 2009 Apr; 35(2):212-8. PubMed ID: 19335794
[TBL] [Abstract][Full Text] [Related]
4. The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines.
Zhou J; Ye F; Chen H; Lv W; Gan N
J Int Med Res; 2007; 35(3):290-300. PubMed ID: 17593856
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.
da Silva RF; Yoshida A; Cardozo DM; Jales RM; Paust S; Derchain S; Guimarães F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28513532
[TBL] [Abstract][Full Text] [Related]
6. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer.
Zhu Q; Wu X; Wu Y; Wang X
Oncol Rep; 2016 Dec; 36(6):3472-3478. PubMed ID: 27748885
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of IL-10 and TGF-β levels and myeloid and lymphoid dendritic cells in ovarian cancer patients.
Wertel I; Polak G; Tarkowski R; Kotarska M
Ginekol Pol; 2011 Jun; 82(6):414-20. PubMed ID: 21853929
[TBL] [Abstract][Full Text] [Related]
8. Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor.
Orengo AM; Fabbi M; Miglietta L; Andreani C; Bruzzone M; Puppo A; Cristoforoni P; Centurioni MG; Gualco M; Salvi S; Boccardo S; Truini M; Piazza T; Canevari S; Mezzanzanica D; Ferrini S
Int J Cancer; 2011 Sep; 129(5):1116-25. PubMed ID: 21710494
[TBL] [Abstract][Full Text] [Related]
9. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer.
Gastl G; Plante M; Finstad CL; Wong GY; Federici MG; Bander NH; Rubin SC
Br J Haematol; 1993 Mar; 83(3):433-41. PubMed ID: 8485049
[TBL] [Abstract][Full Text] [Related]
10. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
[TBL] [Abstract][Full Text] [Related]
11. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
Stadlmann S; Amberger A; Pollheimer J; Gastl G; Offner FA; Margreiter R; Zeimet AG
Gynecol Oncol; 2005 Jun; 97(3):784-9. PubMed ID: 15943987
[TBL] [Abstract][Full Text] [Related]
12. Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors.
Garcia-Soto AE; Schreiber T; Strbo N; Ganjei-Azar P; Miao F; Koru-Sengul T; Simpkins F; Nieves-Neira W; Lucci J; Podack ER
Gynecol Oncol; 2017 Jun; 145(3):413-419. PubMed ID: 28392126
[TBL] [Abstract][Full Text] [Related]
13. Expression of IL-10 in patients with ovarian carcinoma.
Mustea A; Könsgen D; Braicu EI; Pirvulescu C; Sun P; Sofroni D; Lichtenegger W; Sehouli J
Anticancer Res; 2006; 26(2C):1715-8. PubMed ID: 16617566
[TBL] [Abstract][Full Text] [Related]
14. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer.
Cândido EB; Silva LM; Carvalho AT; Lamaita RM; Filho RM; Cota BD; da Silva-Filho AL
Reprod Sci; 2013 Jul; 20(7):828-37. PubMed ID: 23239818
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer.
Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kulesza-Bronczyk B; Kinalski M; Terlikowski SJ
Eur Cytokine Netw; 2013; 24(3):106-13. PubMed ID: 24197277
[TBL] [Abstract][Full Text] [Related]
16. [Tumor-infiltrating dendritic cells in epithelial ovarian carcinoma and correlation with the expression of vascular endothelial growth factor].
Mao YY; Chen HZ; Xie X; Ye DF; Lü WG
Zhonghua Fu Chan Ke Za Zhi; 2004 Oct; 39(10):693-7. PubMed ID: 16144569
[TBL] [Abstract][Full Text] [Related]
17. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients.
Dalal V; Kumar R; Kumar S; Sharma A; Kumar L; Sharma JB; Roy KK; Singh N; Vanamail P
Clin Chim Acta; 2018 Jul; 482():27-32. PubMed ID: 29572186
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
19. The ascites N-glycome of epithelial ovarian cancer patients.
Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862
[TBL] [Abstract][Full Text] [Related]
20. 14-3-3 zeta protein secreted by tumor associated monocytes/macrophages from ascites of epithelial ovarian cancer patients.
Kobayashi R; Deavers M; Patenia R; Rice-Stitt T; Halbe J; Gallardo S; Freedman RS
Cancer Immunol Immunother; 2009 Feb; 58(2):247-58. PubMed ID: 18618111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
